Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (669)	9/1/1999 1:25:00 PM
From: Mike McFarland	Read Replies (2) \| Respond to of 4474

That post of mine triggers the next question: As a result of the work with the EPO monkeys and with the human Growth Hormone in mice there will certainly be a series of improved flavors of ARGENT. Whether those improvements are to the transfection efficiency of the Genovo vector or reduced immunogenic response to ARIAD's dimerizer drug--can these improvements be incorporated into the current GvH trial? Do you suppose the PII for GvH is being designed still? How much information was presented to the FDA for phase I and how far can the next trial wander from Ariad's initial plan? I have not looked into 1903, but I have assumed that it is an earlier rapamycin analog (??) and maybe they have better dimerizers by now? Maybe this is not so important for GvH--where AP1903 is injected however. Thanks to the vanderrhoe post however, it seems to me that the next phase will add the engineered CTL's, so the trial will be about the T-cells, and maybe 1903 is fixed and no imporvement is needed to the dimerizer. This generates yet another question in me: Is it neccessarily true that the same vector would be used on the T cells (ex vivo for BMT) as the vector that is the best for shooting up muscle to generate EPO, Insulin, hGH, or interferon--for the protein therapy side of ARGENT?